Kornimate/medical-research-clean huggingface dataset:
motor-sparing femoral nerve block dose

Conditions: Osteoarthritis, Knee; Knee Injuries

Summary: femoral nerve blocks are commonly used to provide pain control for total knee replacement, anterior cruciate ligament (acl) reconstruction. commonly employed local anesthetic concentrations result in motor block of the quadriceps and constitute an inherent risk factor for patient fall. the aim of this study is to determine the minimum effective concentration of bupivacaine in 90 % of patients (mec90) required for a motor-sparing, successful sensory block of the femoral nerve.

with the approval of ethics committee of the university of chile clinical hospital, approximately 60 patients undergoing acl repair or tkr will be recruited. all blocks will be conducted preoperatively in an induction room.dose assignation will be done using an up-and-down sequential method, where the dose of each subsequent patient depends on the response of the previous patient, called the biased coin design. the assignment of each subsequent concentration will be based on the response of the previous patient.as soon as we recruit 45 patients with random dose assignment, we will terminate the enrollment procedure. the injectate will be prepared and administered by a research assistant using syringes connected to the block needle. the operator and the patient will be blinded to the concentration injected.

Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * american society of anesthesiologists classification 1-3 * body mass index between 20 and 35 exclusion criteria: * adults who are unable to give their own consent * pre-existing neuropathy (assessed by history and physical examination) * coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, international normalized ratio≥ 1.4 or partial prothrombin time ≥ 50) * renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100) * hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100) * allergy to la * pregnancy * prior surgery in the inguinal region * chronic pain syndromes requiring opioid intake at home
study evaluating desvenlafaxine succinate sustained-release (dvs sr) in adult outpatients with major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: a multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (dvs sr) versus placebo in adult outpatients with major depressive disorder.


Eligibility criteria:
inclusion criteria: * male or female outpatients aged 18 years or older who are fluent in written and spoken english. * a primary diagnosis of mdd based on the criteria in the diagnostic and statistical manual of mental disorders, 4th edition (dsm- iv-tr), single or recurrent episode, without psychotic features. * a ham-d17 total score ≥20 at the screening and baseline (study day -1) visits and no more than a 4-point improvement from screening to baseline. exclusion criteria: * significant risk of suicide based on clinical judgment. * current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder. * current generalized anxiety disorder, panic disorder, or social anxiety disorder. * history or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs. * any unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic, or other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.
cardiac magnetic resonance utilities in the evaluation of ischemic heart disease

Conditions: Myocardial Ischemia

Summary: the purpose of this study is to evaluate cardiac magnetic resonance utilities in the ischemic heart disease as topographical correlation between ischemic territory injury and coronary angiography.

assessing the accuracy of cardio-rm identifying ischemic territories and their correspondence to the presence of critical coronary lesions, comparing the presence, extent and regional inducible ischaemia in the cardiac-mri with the presence and characteristics of vascular lesions in coronary angiography. in particular, the study aims to evaluate the correlation between topography and function of the ischemic area revealed by the resonance and coronary artery disease documented coronary angiography.

Eligibility criteria:
inclusion criteria: 1. patients with suspected ischemic heart disease or recurrent myocardial ischemic symptoms defined as: * presence of: * chest pain related to the effort lasting 5-20 minutes, and / or * positive stress test for inducible myocardial ischemia * presence of at least one of the following risk factors: smoke family history of cardiovascular disease hypertension dyslipidemia diabetes mellitus nid / id 2. no contraindications to perform coronary angiography 3. informed written consent to the processing of personal and sensible data, signed and dated by the patient. exclusion criteria: * unstable angina; * severe aortic stenosis * hypertrophic cardiomyopathy * pacemaker and \\ or defibrillator * coronary stent implantation in 90 days before cardiac mri * intracranial metal clips * severe hypertension (systolic blood pressure\> 240 mmhg, and diastolic blood pressure above 120 mmhg) * ventricular thrombosis and \\ or atrial * aortic aneurysm and \\ or aortic dissection * myocarditis, endocarditis, pericarditis * critical stenosis of the left notes * state of severe anxiety or claustrophobia * contraindications to the use of atropine (bav advanced glaucoma, pyloric stenosis, prostatic hypertrophy)

Keywords: cardiac magnetic resonance myocardial ischemia coronary artery disease suspected myocardial ischemia
efficacy and safety of risedronate therapy administered 35 mg once a week in men with osteoporosis

Conditions: Other Osteoporosis

Summary: two year study to determine the safety and efficacy of weekly 35 mg risedronate doses in men with osteoporosis followed by a two year follow-up study.


Eligibility criteria:
inclusion criteria: * documented osteoporosis of the femoral neck and lumbar spine exclusion criteria: * bmi greater than or equal to 35
exploration of noninvasive differential diagnosis of benign and malignant liver tumors

Conditions: Liver Tumor

Summary: to explore an effective noninvasive method for differential diagnosis of liver tumors.

a retrospective study was performed to assess the performance of certain ultrasound-based parameters, in distinguishing benign from malignant with liver biopsy as the gold standard. demographic data, clinical information and serological data were obtained from participants who were retrospectively enrolled. receiver operating characteristic (roc) curve analysis was conducted, including calculation of the optimal area under the roc curve (auc), to assess the performance of these measures in distinguishing between benign and malignant in patients with or without chronic liver disease.

Eligibility criteria:
inclusion criteria: (1) age 18-70 years; (2) liver examination performed for all patients prior to us-guided liver biopsy or surgery; (3) tumor can be visualized in conventional us; (4) largest tumor sectional area saved in dicom format for use in later analyses; (5) a histopathological diagnosis made either from us-guided liver biopsy or surgical resection; (6) suitable routine clinical and us data obtained within 7 days of the histopathological diagnosis. exclusion criteria: (1) unavailable pathological diagnosis; (2) liver metastatic tumors; (3) poor quality us images; and (4) a past history of surgical resection, percutaneous local ablation, radiation, transarterial and systemic therapies or liver transplantation.

Keywords: liver tumors benign malignant differential diagnosis
follow-up study of safety and efficacy in subjects who completed pneumostem® phase ii (mp-cr-012) clinical trial

Conditions: Bronchopulmonary Dysplasia; BPD

Summary: this is a follow-up study to investigate the long-term safety and efficacy of pneumostem® versus placebo, for the treatment of bpd in premature infants. subjects who participated in and completed the initial stage of the phase ii trial (nct03392467) will be followed-up until 60 months of corrected age

subjects who completed the initial stage of the phase ii clinical trial will be followed-up at 7 additional visits: 6, 12,18, 24 months corrected age, 36, 48, and 60 months after birth.

Eligibility criteria:
inclusion criteria: * subject who enrolled in phase 2 clinical trial of pneumostem® to evaluate efficacy and safety, and were administered with investigational product * subject with a written consent form signed by a legal representative or a parent upon explanation of the clinical trial exclusion criteria: * subject whose parent or legal representative does not agree to participate in the study * subject who is considered inappropriate to participate in the study by the investigator

Keywords: human umbilical cord blood derived mesenchymal stem cells bronchopulmonary dysplasia premature infants
very-low-density-lipoprotein-triglyceride(vldl-tg) metabolism during acute hyperglycemia

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to estimate the acute effect of hyperglycemia on very-low-density-lipoprotein-triglyceride(vldl-tg) secretion.


Eligibility criteria:
inclusion criteria: 1. type 1 diabetes 2. age 18-50 years exclusion criteria: 1. smoking 2. alcohol abuse 3. use of medications (except insulin in diabetics)

Keywords: type 1 diabetes very-low-density-lipoprotein(vldl) hyperglycemia
a comparison of stroke volume variation for prediction of fluid responsiveness

Conditions: Stroke Volume Variation; SVV-FloTrac; Thoracic Electrical Bioimpedance; Fluid Responsiveness

Summary: stroke volume variation (svv) is an indicator used to assess the patient's volume status. the flotrac system (edwards lifesciences, irvine, ca) continuously monitors cardiac output (co) and svv (svv-flotrac) by analyzing the systemic arterial pressure wave. numerous studies have demonstrated that svv-flotrac serves as a reliable indicator of fluid responsiveness. however, its peripheral invasiveness raises concerns about susceptibility to reflecting waves, damping, and vascular tone influences.in contrast, transthoracic electrical bioimpedance (bioz.com™) offers a non-invasive approach for continuously monitoring various hemodynamic variables. in this study, the primary aim was to assess the agreement between simultaneously measured svv-flotrac and svv-bioz.


Eligibility criteria:
inclusion criteria: * age 18≤ age ≤65 * patients undergoinglaparoscopic elective surgery for gastrointestinal tumors under general anesthesia * 18 kg/m2≤bmi≤30 kg/m2 * asa classification i-iii * patients signed informed consent form exclusion criteria: * arrhythmias * the patient is diagnosed with severe cardiovascular disease（pulmonary arterial hypertension、left ventricular ejection fraction\< 50%、aortic aneurysm、extensive peripheral arterial occlusive disease,、significant valvulopathy） * severe heart failure (mets\<4) * the patient is diagnosed with severe hepatic dysfunction (childepugh class c) * the patient is diagnosed with severe renal dysfunction (undergoing dialysis before surgery) * there is an infectious lesion on the skin or subcutaneous tissue where the non-invasive electrode piece is placed * history of allergy to anesthetic drugs * weight\<40kg * allergies to 6% hydroxyethyl starch, fresenius kabi, deutschland
determining normal range for free light chains in serum among twins

Conditions: Multiple Myeloma

Summary: the objective of this study is to recruit healthy adult identical and fraternal twins for the collection of one teaspoon of blood to be sent to the clinical lab at san francisco general hospital. the serum will be tested to determine the reference range for free light chains.

serum free light chains are used to assist in the diagnosis of multiple myeloma. the test measures kappa (k) and lambda (l) chains, and the calculation of the ratio of kappa to lambda (k/l). previous studies have shown that the k/l ratio does not change over time (1 year). the hypothesis of this study is that healthy twins will have a k/l ratio that are close to each other in value, suggesting that this ratio is genetically linked.

Eligibility criteria:
inclusion criteria: * healthy subjects 18-80 years. * must be an identical or fraternal twin (both must be recruited) exclusion criteria: * symptoms suggestive of multiple myeloma (e.g., renal insufficiency, anemia, bone pain) -

Keywords: free light chains healthy twins
poorly differentiated adenocarcinoma of the jejunum in a patient with peutz-jeghers syndrome: a case report

Conditions: Peutz-Jeghers Syndrome

Summary: our study is a case report of one of the rarest risk factor, peutz-jeghers syndrome, of small bowel malignancy detected in a patient with poorly differentiated adenocarcinoma of small bowel(jejunum)

case presentation: a 25-year-old male patient presented to the emergency department with generalized peritonitis caused by a perforated jejunal mass. the patient underwent an emergency exploratory laparotomy. there was 800 ml of thin pus in the peritoneal cavity and 5 cm by 6 cm perforated mass over the jejunum, 30cm from the ligament of the treitz, which extends to the mesentery. palpable jejunal mesenteric lymphadenopathies were found. there were palpable intraluminal polyps with an inverted serosal surface for some of them, which were identified as 10cm proximal and 20cm distal to the mass. the pus was sucked out, and the mass was resected with its mesenteric lymph nodes and segments containing polyps, a total of 40cm of jejunum. subsequently, end-to-end hand-sewn anastomosis was performed, and the abdomen was closed. the histopathology report showed poorly differentiated adenocarcinoma, stage iiic (pt3, pn2), and peutz-jeghers polyps, suggesting peutz-jeghers syndrome. lympho-vascular invasion was also noted. the tumor has affected seven of the 12 lymph nodes that have been identified. after 6weeks of uneventful follow-up at the surgical referral clinic, the patient was referred to the oncology department for adjuvant chemotherapy.

Eligibility criteria:
inclusion criteria: * not necessary exclusion criteria: * not necessary
a study of enzastaurin in patients with leukemia

Conditions: Leukemia, Lymphocytic

Summary: the primary objective of this study is to see if enzastaurin affects the pgsk3 beta level in b-cell chronic lymphocytic leukemia (b-cll) cells.


Eligibility criteria:
inclusion criteria: patients are eligible to be included in the study only if they meet all of the following criteria: 1. patients with b-cell cll as diagnosed by expression of cd19, cd5, and cd23 by flow cytometry. 2. rai stage iii or iv disease or earlier stage disease with indications for therapy per nci working group criteria (cheson et al. 1996) 3. absolute lymphocyte count \> or = to 5,000/microliter, with a lymphocyte wbc differential of \> or = to 70%. 4. platelet count \>20,000/microliter. 5. adequate organ function, including the following: * hepatic: bilirubin \< or = to 1.5 times the upper limit of normal (x uln); alkaline phosphatase (alp), aspartate transaminase (ast), and alanine transaminase (alt) \< or = to 2.5 x uln * renal: serum creatinine \< or = to 1.5 x uln. exclusion criteria: patients will be excluded from the study if they meet any of the following criteria: 1. are unable to swallow tablets. 2. are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin. 3. are pregnant or breastfeeding. 4. have central nervous system (cns) metastases (unless the patient has completed successful local therapy for cns metastases and has been off of corticosteroids for at least 4 weeks before starting study therapy). 5. have a serious concomitant systemic disorder (including active bacterial, fungal, or viral infection) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol.
use of ngal for fluid dosing and crrt initiation in pediatric and neonatal aki

Conditions: Acute Kidney Injury; Acute Kidney Injury Due to Sepsis; Neonatal Sepsis

Summary: this study will follow patients admitted to the picu with sepsis, nicu with sepsis or after abdominal surgery, or cicu who are identified as being at risk for developing acute kidney injury. the investigators will use risk-stratification, biomarker testing, and a functional assessment to predict children and neonates who will become fluid overloaded and develop severe acute kidney injury.

in the pediatric population, acute kidney injury (aki) is commonly observed in critically ill patients. at this time, there are no standardized care pathways that begin at identifying patients at risk for developing aki and progress through to early recognition and treatment. through previous work, the investigators have integrated a risk-stratification tool (renal angina index or rai) and a urine biomarker (ngal) to try to identify picu patients at risk versus not at-risk for developing aki. through this study, the investigators will tailor the rai to the septic population in the picu, create a new nicu rai, and investigate the utility of the cicu specific rai in a prospective population. biomarker testing will be used to further risk-stratify those patients deemed at highest risk through the rai.

Eligibility criteria:
inclusion criteria: * admitted to the pediatric intensive care unit (picu), cardiac intensive care unit (cicu), or neonatal intensive care unit (nicu) at participating institution exclusion criteria: * baseline chronic kidney disease (ckd) stage iv or v (estimated gfr \<60 ml/min/1.736m2) * history of kidney transplant within the previous 90 days * ongoing aki or acute kidney disease (akd) at icu admission requiring renal replacement therapy initiated prior to icu admission * acute dnr order or clinical team is not committed to escalating medical care * anticipated to require intensive care for less than 48 hours

Keywords: renal angina index ngal
cardiac rehab retrospective review (cr3)

Conditions: Sudden Cardiac Death; Heart Failure; Ventricular Arrythmia; Ventricular Tachycardia; Ventricular Fibrillation

Summary: all patients enrolled in the austrian lifevest registry will be retrospectively screened for successfully completed ambulatory or stationary rehabilitation program. baseline characteristics, complete rehab data, outcomes and follow up data, as well as wearable cardioverter defibrillator(wcd)-derived data will be collected from these patients. specifically, performance data from the start of the exercise training (et) will be compared to the end of et; including type of training, exertion, time and duration will be collected. in addition, wcd recorded data such as automatically and manually recorded ecgs, compliance, and trends data will be collected.


Eligibility criteria:
inclusion criteria: * prescribed wcd as part of the austrian wcd registry population from 2014-2018 * partial (\>50%) or full completion of a rehabilitation program when wearing the wcd in austria * ≥18 years old and able to give informed consent exclusion criteria: - none

Keywords: wearable cardioverter-defibrillator cardiac rehabilitation
diabetes care management compared to standard diabetes care in adolescents and young adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: structured transition program for adolescents and young adults with type 1 diabetes (t1d) improves diabetes clinic attendance as well as glycemic control after transition from pediatric to adult diabetes care.

the purpose of this study is to determine if a structured transition program for adolescents and young adults with type 1 diabetes (t1d) improves diabetes clinic attendance and management as well as glycemic control after transition from pediatric to adult diabetes care.

Eligibility criteria:
inclusion criteria: * established t1d diagnosis for a minimum of one year (chosen to allow time for adjustment to a new diagnosis and more stable disease control). * between the ages of 17 and 20 years. it is left to the clinical judgment of the pediatric endocrinologist to determine individually the appropriate age of the transition for each subject * at least 1 visit during the previous year with the pediatric endocrinologist at a diabetes clinic (aim is to minimize the non-adherence with the intervention). * ability to participate in all aspects of this clinical trial. * written informed consent/assent must be obtained and documented. * resident of ontario. exclusion criteria: * pregnant or lactating females or intent to become pregnant during the next 3 years. * conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study. * prior enrollment in the current study. * current participation in another clinical trial or participation in another clinical trial in the 6 months prior to enrollment.

Keywords: type 1 diabetes 17 to 20 years of age
myths about bipolar affective disorder: the role of structured group psychoeducation therapy

Conditions: Bipolar Affective Disorder

Summary: this study will examine: 1) the impact of psycho education group therapy sessions relating to beliefs/myths associated with bipolar affective disorder (bad) on the emotional wellbeing, clinical course and cognition of individuals diagnosed with bad 2) will examine the existence of those same beliefs among the various caregivers - psychiatrists, general practitioners, social workers, and psychiatric nurses. the investigators hypothesize that psychoeducation group therapy will be effective in refuting the myths and will lead to better treatment adherence, longer remissions, fewer hospitalizations, improved self esteem, increased optimism, and better control over the disease process. the investigators also believe that they will identify some beliefs/myths or preconceived notions that are common to both caregivers and individuals with bad.

methods: effect psychoeducation: study population - 30 patients diagnosed with bad treated in the outpatient clinic, in a state of remission will be evaluated with the hamilton rating scale for depression, young mania rating scale, and will then participate in 7 weekly sessions of brief structured psycho education therapy control group - 30 patients diagnosed with bad treated in the outpatient clinic, in a state of remission will be evaluated with the hamilton rating scale for depression, young mania rating scale. in addition both groups will complete the snyder hope scale, accepting the mental illness label scale and a questionnaire regarding myths in bad prior to the study, and when the study group finishes their group therapy sessions. (controls will not participate in the psychoeducation group therapy). caregivers beliefs: 50 caregivers from various professions will complete the questionnaire regarding the myths, once only.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of bad * state of remission exclusion criteria: * ham-d score \< 10 * ymrs score \< 12 * has a guardian for either self or property

Keywords: bipolar affective disorder myths preconceived notions stigma hope